Captopril pretreatment protects the lung against severe acute pancreatitis induced injury via inhibiting angiotensin II production and suppressing Rho/ROCK pathway  by Yu, Qi-Hong et al.
Kaohsiung Journal of Medical Sciences (2016) 32, 439e445Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLECaptopril pretreatment protects the lung against
severe acute pancreatitis induced injury via
inhibiting angiotensin II production and
suppressing Rho/ROCK pathway
Qi-Hong Yu, Jie-Fang Guo, Yan Chen, Xiao-Rong Guo, Yi-Qi Du,
Zhao-Shen Li*Department of Gastroenterology, Changhai Hospital, Second Military Medical University,
Shanghai, ChinaReceived 27 May 2016; accepted 18 July 2016




Ang II receptor type 1;
Angiotensin II;
Rho/ROCK pathwayConflicts of interest: All authors d
* Corresponding author. Department
Yangpu District, 200433 Shanghai, Chi
E-mail address: Lzssmmu@163.com
http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2016, Kaohsiu
CC BY-NC-ND license (http://creativeAbstract Acute pancreatitis (AP) usually causes acute lung injury, which is also known as acute
pancreatitis associated lung injury (APALI). This study aimed to investigate whether captopril
pretreatmentwas able to protect lung against APALI via inhibiting angiotensin II (Ang II) production
and suppressing Rho/ROCK (Rho kinase) pathway in rats. Severe AP (SAP) was introduced to rats by
bileepancreatic duct retrograde injection of 5% sodium taurocholate. Rats were randomly divided
into three groups. In the sham group, sham operation was performed; in the SAP group, SAP was
introduced; in the pre-cplþ SAP group, rats were intragastrically injected with 5 mg/kg captopril
1 hour prior to SAP induction. Pathological examination of the lung and pancreas, evaluation of
pulmonary vascular permeability by wet/dry ratio and Evans Blue staining, detection of serum
amylase, Western blot assay for Ang II receptor type 1 (AT1), RhoA, ROCK (Rho kinase), and MLCK
(myosin light chain kinase) were performed after the animalswere sacrificed at 24 hours. After the
surgery, characteristic findings of pancreatitis were observed, accompanied by lung injury. The
serum amylase, Ang II, and lung expression of AT1, RhoA, ROCK, and MLCK increased dramatically
in SAP rats. However, captopril pretreatment improved the histological changes, reduced the
pathological score of the pancreas and lung, inhibited serum amylase and Ang II production,
and decreased expression of AT1, RhoA, ROCK, and MLCK in the lung. These findings suggest that
captopril pretreatment is able to protect the lung against APALI, which is, at least partially,
related to the inhibition of Ang II production and the suppression of the Rho/ROCK pathway.
Copyrightª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).eclare no conflicts of interest.
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Acute pancreatitis (AP) is a reversible inflammatory process
of the pancreas. It is a common disease in clinical practice
with rapid disease progression and high risk for death [1].
The incidence of AP is in the range of 300 or more patients
per million annually [2,3], and about 10e20% of AP patients
are classified as severe (SAP), of whom 10e25% will die
despite the improvements in critical care [3,4]. Although
the disease process may be limited to the pancreas, it can
also involve peripancreatic tissues or other distant organs.
Lung injury is the most pertinent manifestation of extra-
abdominal organ dysfunction in SAP [1]. Approximately
one-third of patients will develop acute lung injury (ALI),
also known as acute pancreatitis-associated lung injury
(APALI), and acute respiratory distress syndrome, which
account for 60% of all deaths within the 1st week [5].
Although the pathogenesis of APALI has been extensively
studied, the specific mechanism underlying the pathogen-
esis of APALI is still not completely elucidated [1].
The renineangiotensin system (RAS) was initially
considered a circulating humoral system, with functions in
regulating blood pressure and in sodium and water ho-
meostasis [6]. In recent years, studies reveal that RAS is
closely related to lung injury [7]. Besides the “classical”
humoral RAS, many tissues including the lung have local
(tissue or paracrine) RAS that contains the different com-
ponents of the circulating RAS [8,9]. Angiotensin II (Ang II) is
the most important effector peptide of the RAS; its actions
are mediated by two main cell receptors: type 1 and type 2
(AT1 and AT2) receptors, and most of the recognized
functions of Ang II involve AT1 [10]. Recent studies have
demonstrated that Ang II is involved in the pathogenesis of
lung injury in different animal models [11,12], and inhibi-
tion of the Ang II signaling pathway and/or RAS has been
found to be protective on lung injury [13].
In the presence of lung injury, pulmonary microvascular
permeability increases and protein-rich transudate spills
into the alveolar spaces, resulting in compromised lung
compliance, which are hallmarks of APALI. RhoA is one of
the important molecules involved in the regulation of pul-
monary vascular endothelial cell permeability [14]. RhoA
can activate downstream Rho kinase (ROCK), leading to the
inactivation of myosin light chain kinase (MLCK) because of
its phosphorylation. The inactivated MLCK fails to dephos-
phorylate myosin light chain (MLC), causing the increase in
the cytoplasma phosphorylated MLC (MLCP), which finally
increases the endothelial cell permeability [15]. There is
evidence showing that ROCK is involved in Ang II-induced
hypertrophy of rat vascular smooth muscle cells [16].
The aim of this study was to investigate the protective
effects of captopril pretreatment on APALI and explore
whether these effects of captopril were related to the
reduction in Ang II and inhibition of the Rho/ROCK pathway.
Methods
Animals
Adults male SpragueeDawley rats weighing 200e220 g
(nZ 90) were purchased from the Experimental AnimalCenter of the Second Military Medical University, Shanghai,
China. Rats were allowed to acclimate to the environment
for 7 days and given ad libitum access to water and food.
After surgery, the animals were housed independently in
cages. This study was approved by the Ethics Committee of
the Second Military Medical University.
Establishment of rat APALI model
AP was induced based on a previously described method [17]
with minor modifications. Rats were subjected to food
deprivation for 12 hours prior to the surgery. After weighing,
the animals were anesthetized intraperitoneally with 10%
chloral hydrate (Shanghai Biochemical Reagent Factory,
Shanghai, China) at 0.4 mL/100 g. Then, they were placed in
a supine position, and a midline incision was made at the
abdomen. The descending duodenum was identified and
exposed, and the trend of the bileepancreatic duct was
discerned. The bile duct was clamped at the site of the
hepatoduodenal ligament close to the porta hepatis, and
then 5% sodium taurocholate (Sigma-Aldrich, St. Louis, MO,
USA) at 0.1 mL/100 g was retrogradely infused into the distal
end of the bileepancreatic duct. The proximal bile duct was
temporarily clamped at the porta hepatis with a vascular
clamp. Subsequently, the vascular clamp was removed and
the duodenal and abdominal woundswere closed. Rats in the
sham group underwent only a laparotomy and subsequent
exposure of theduodenum.Theabovementionedprocedures
were conducted under an asceptic condition.
Grouping and treatments
Rats were randomly divided into three groups (nZ 30 per
group): sham group, SAP group, and pre-cpl þ SAP group. In
the sham group, rats received intragastric injection of
normal saline and sham surgery; in the SAP group, SAP was
induced after intragastrical injection of normal saline; the
in pre-cpl þ SAP group, rats were intragastrically injected
with captopril (Sigma-Aldrich) at 5 mg/kg (about 0.4 mL) 1
hour prior to SAP.
Detection of serum amylase
Twenty-four hours after the surgery, rats were sacrificed
and blood was collected from the heart. Blood was centri-
fuged at 1000 g for 5 minutes at 4C, and the supernatant
was collected and processed for the detection of serum
amylase with an automatic biochemical analyzer.
Pathological examinations of the lung and pancreas
Twenty-four hours after the surgery, rats were sacrificed,
and the left lung and pancreas were collected and fixed in
4% paraformaldehyde at 4C. After dehydration in ethanol,
tissues were embedded in paraffin and then cut into 4-mm
sections. Then, these sections were processed for hema-
toxylin and eosin staining.
The morphological evidence of lung injury in the rats
was evaluated by two blinded investigators. Alveolar
membrane thickness and cellularity were evaluated by
estimation of the fraction of the microscope field occupied
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[18]. Pancreatic sections were subjected to hematoxylin
and eosin staining and graded in a blinded manner using a
scale from 0 to 4 for the degree of vacuolization, inflam-
mation, necrosis, and edema according to the histological
scoring system reported by Rongione et al [19]. Three fields
at a high magnification ( 400) were randomly selected and
scored, and the mean was calculated.
Detection of lung wet/dry ratio and pulmonary
vascular permeability
Twenty-four hours after surgery, rats were sacrificed and
the right lung was collected and washed in phosphate-
buffered saline (PBS). The water on the lung was removed
with filters, and then the right lung was weighed (wet
weight). After drying in an oven at 60C for 24 hours, the
right lung was weighed (dry weight). The lung wet/dry ratio
(W/D) was calculated to reflect the severity of lung edema.
Thirty minutes before they were sacrificed, the rats
were injected with 0.5% Evans Blue at 30 mg/kg via the tail
vein. After anesthesia, thoracotomy was performed, and an
incision was made at the apex of the heart. Cold PBS was
injected via the right ventricle to lavage the lung. When no
blood was observed in the lung, the lung was collected and
mixed with formamide (100 mg tissues/1 mL formamide)
for the extraction of Evans Blue. The mixture was stored at
37C for 72 hours, and the optical density of the superna-
tant was determined after centrifugation. Standard curve
was delineated, and the content of Evans Blue was calcu-
lated according to the standard curve (mg/mg tissues).
Detection of lung Ang II
Twenty-four hours after surgery, ratswere sacrificed, and the
left lungs were collected and stored at e80C. Prior to
detection, the lung tissues were homogenized in 1mL normal
saline and then transferred into an EP tube, followed by
centrifugation at 10,000 g for 15 minutes. The supernatant
was collected for the detection of Ang II with a kit (Sigma-
Aldrich) according to manufacturer’s instructions.
Detection of AT1, RhoA, ROCK, and MLCK
expressions by Western blot assay
The left lung tissues were lysed and centrifuged at 10,000g
for 15 minutes at 4C. The supernatant was collected, and
its protein concentration was determined with the
bicinchoninic acid (BCA) method. Then, the supernatant
was subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis for 2 hours for the separation of pro-
teins at 8 V/cm in stacking gel and 15 V/cm in separating
gel. Then, the proteins were transferred onto nitrocellulose
membrane at 80 mA for 2 hours. After blocking in nonfat
milk for 30 minutes, the membrane was washed in PBS-T
thrice (15 minutes for each) and then incubated with pri-
mary antibody (1:500) at 4C over night. After washing in
PBST-T thrice (15 minutes for each), the membrane was
incubated with secondary antibody (1:200) at room tem-
perature for 2 hours and then washed in PBS-T thrice (15minutes for each). Visualization was done with electro-
chemiluminescence (ECL), and the optical density of each
protein band was determined.
Statistical analysis
Data are expressed as mean standard deviation (X  s).
Statistical analysis was performed with SPSS version 16.0
(SPSS Inc., Chicago, IL, USA), and comparisons were done
with one way analysis of variance among groups, followed
by SNK-q test between two groups. A p value < 0.05 was
considered statistically significant.
Results
Pathological examination of the lung and pancreas
In the sham group, there were no obvious changes in the
pancreas. The pancreatic structure was clear, cell
morphology was normal, and there were no evident inter-
stitial edema, no hemorrhage, and no necrosis. The path-
ological score of the pancreas was 0.5 0.5. In the SAP
group, there were disruption of pancreatic acini and lobular
structure, massive hemorrhagic and necrotic areas, and
infiltration of a large amount of neutrophils, and the
pathological score was 9.1 1.8, which was significantly
higher than that in the sham group (p < 0.05). In the pre-cpl
þ SAP group, there was pancreatic acini swelling; hemor-
rhage and necrosis were also observed in a few pancreatic
acini, lobular space was enlarged, there was infiltration of
some inflammatory cells, and the pathological score
(5.8 0.9) decreased markedly when compared with the
SAP group (p < 0.05; Figure 1).
In the sham group, the alveolar structure was normal
and clear, there were no infiltration of inflammatory cells in
the alveolar wall and interstitium, and the score of lung
injury was 0.6 0.5. However, in the SAP group, there was
diffuse interstitial edema of the lung, broadening of lung
interstitium, infiltration of a large amount of neutrophils
and mononuclear cells into lung interstitium, alveolar space
disruption, and disordered structure of some alveoli. The
pathological score was 3.7 0.7 (p < 0.05 vs. sham group).
In the pre-cpl þ SAP group, there were mild lung edema,
infiltration of a few inflammatory cells, and attenuated
thickening of lung interstitium, and the alveolar structure
was largely intact. The pathological score was 2.6 0.5. A
significant difference in pathological score was observed
among the three groups (p < 0.05; Figure 1).
Lung W/D ratio and vascular permeability
As shown in Figure 2A, the W/D ratio was 5.74 0.67 in the
SAP group, which was significantly higher than that in the
sham group (3.92 0.26; p < 0.01) and in the pre-cpl þ SAP
group (4.25 0.61; p < 0.05).
As shown in Figure 2B, the Evans Blue content was
36.78 7.13 mg/mg wet weight in the sham group, which
was markedly lower than that in the SAP group
(94.62 10.58 mg/mg wet weight; p < 0.01). However, the
Figure 1. HE staining of the pancreas and lung. The lung and pancreas were collected for HE staining. Results showed the lung
and pancreas were intact in the sham group, but were significantly damaged in the SAP group. With captopril pretreatment (pre-cpl
þ SAP group), pancreatitis and SAP-induced lung injury exhibited significant improvements, as shown by the reduction in patho-
logical scores. (A, B) pancreas; (C, D) lung. Scale barZ 20 mm. * p < 0.05 versus SAP. # p < 0.05 versus sham. HEZ eosin and
hematoxylin; SAPZ severe acute pancreatitis.
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SAP group when compared with the SAP group (p < 0.01).Contents of serum amylase and lung Ang II
As shown in Figure 3A, the serum amylase content was
685.4 114.1 U/L in the sham group, but increased signif-
icantly in the SAP group (5695.7 1218.3 U/L; p < 0.01).
However, serum amylase content in the pre-cpl þ SAP
group (3862.1 538.5 U/L) markedly decreased when
compared with the SAP group (p < 0.05).
As shown in Figure 3B, the lung Ang II content was
103.72 15.05 pg/mL in the sham group, but dramatically
increased in the SAP group (287.16 46.90 pg/mL; p <
0.01). Moreover, the lung Ang II content in the pre-cpl þ
SAP group (211.14 22.53 pg/mL) was significantly lower
than in the SAP group, although that in the pre-cpl þ SAPFigure 2. (A) Lung wet/dry weight ratio. (B) Evans Blue staining.
with captopril pretreatment, (A) the lung W/D ratio reduced sign
evaluate the vascular permeability. (B) Results showed captopril p
vascular permeability. * p < 0.05 versus SAP. ** p < 0.01 versus SAP.
ratioZwet/dry ratio.group was still higher than that in the sham group (p <
0.05).
AT1 receptor expression in the lung
Western blot assay showed that the AT1 receptor expres-
sion was 0.13 0.07 in the sham group. At 24 hours after
SAP, the AT1 receptor expression was 0.59 0.14, which
was markedly higher than that in the sham group (p <
0.01). In the pre-cpl þ SAP group, AT1 receptor expression
decreased markedly when compared with the SAP group
(0.35 0.11; p < 0.01; Figure 4A).
RhoA, ROCK, and MOCK expression in the lung
The Western blot assay showed that the RhoA protein
expression was 0.33 0.08 in the sham group, 1.25 0.29After SAP, the lung W/D ratio increased significantly. However,
ificantly. Moreover, Evans blue staining was also performed to
retreatment was able to prevent SAP-induced increase in lung
## p < 0.01 versus sham. SAPZ severe acute pancreatitis; W/D
Figure 3. (A) Serum amylase content and (B) lung Ang II content. ELISA was used to detect the serum amylase content and lung
Ang II content. Results showed serum amylase increased markedly following SAP. In addition, (A) captopril pretreatment attenu-
ated pancreatitis demonstrated by markedly reduced serum amylase content. (B) Ang II in the lung also increased after SAP, but
reduced significantly in the presence of captopril pretreatment. * p < 0.05 versus SAP. ## p < 0.01 versus sham. Ang IIZ angiotensin
II; ELISAZ enzyme-linked immunosorbent assay; SAPZ severe acute pancreatitis.
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group, showing marked differences among the three groups
(p < 0.01; Figure 4B).
The Western blot assay showed that the ROCK1 protein
expression was 0.29 0.10 in the sham group and
0.73 0.16 in the SAP group, showing marked differences
between them (p < 0.01; Figure 4C). In the pre-cpl þ SAP
group, ROCK1 protein expression decreased slightly
(0.60 0.12; p > 0.05 vs. SAP group). ROCK2 protein
expression was 0.12 0.03 in the sham group and
0.65 0.15 in the SAP group, showing significant difference
(p < 0.01; Figure 4D). In the pre-cpl þ SAP group, ROCK2
protein expression decreased significantly (0.19 0.04; p <
0.01) when compared with the SAP group.
As shown in Figure 4E, MLCK protein expression was
0.27 0.05 in the sham group, 0.84 0.12 in the SAP group,
and 0.71 0.10 in the pre-cpl þ SAP group, showing marked
differences among these groups (p < 0.01 or p < 0.05).Figure 4. Detection of protein expressions of AT1, Rho, ROCK1, R
of AT1, Rho, ROCK2, and MLCK increased significantly in rats with
pretreatment. Captopril pretreatment failed to inhibit the increase
** p < 0.01 versus SAP. ## p < 0.01 versus sham. AT1Z Ang II rec
kinase; SAPZ severe acute pancreatitis.Discussion
SAP is a common disease with multiple complications, high
mortality, and complicated pathogenesis, and APALI is a
major cause of death in SAP patients [2,5]. In this study,
SAP and APALI in rats were successfully established by
retrograde pancreatic duct injection of sodium
taurocholate.
RAS, which is vital in the regulation of blood pressure,
electrolytes, and total body volume, is closely related to
lung injury [7]. Studies have shown that Ang II as an
important component of RAS is involved in the pathogenesis
of lung injury in different models, and most actions of Ang II
are related to the AT1 receptor. Thus, strategies that aim to
inhibit Ang II production and/or its receptor have been
found to exert protective effects [11,12]. Deng et al [11]
found endogenous that Ang II could inhibit alveolar fluid
clearance and dysregulate a-epithelial sodium channelOCK2, and MLCK by Western blot assay. The protein expressions
SAP, but decreased dramatically in the presence of captopril
in ROCK1 expression of rat lung after SAP. * p < 0.05 versus SAP.
eptor type 1; MLCKZmyosin light chain kinase; ROCKZ Rho
444 Q.-H. Yu et al.expression via AT1 receptors, which contributed to the
alveolar filling and pulmonary edema in lipopolysaccharide-
induced ALI [11]. In radiation-induced lung injury, Ang II
significantly increased in the lung even at 6 months after
irradiation [12]. In addition, some investigators have shown
that the reduction in Ang II production, the increased
metabolism of Ang II into angiotensins 1e7, and the
antagonism of AT1 receptor are able to protect the lung
against injury in several animal models [13,20e22]. In the
present study, our results also showed that lung Ang II
increased significantly in SAP animals with APALI, accom-
panied by increased expression of AT1 in the lung. After
pretreatment with captopril, the lung Ang II decreased
markedly in SAP rats, accompanied by a reduction in AT1
expression and the improvements of lung and pancreatic
injuries. These findings indicate that Ang II is involved in
the pathogenesis of SAP and APALI, and captopril pre-
treatment may protect the lung against APALI via inhibiting
Ang II production in the lung.
APALI is a consequence of a pronounced systemic in-
flammatory response with increased endothelial and
epithelial barrier permeability, which may cause the
leakage of a protein-rich exudate into the alveolar space
and interstitial tissues, thus compromising oxygenation and
gas exchange [1]. Therefore, the vascular permeability of
the lung is crucial in the pathogenesis of APALI. Vascular
endothelial permeability is influenced and regulated by
many signaling pathways. The vascular endothelial shrink-
ability is pivotal for the vascular endothelial barrier
(permeability). The shrinkability of endothelial cells is
regulated by the cytoskeletal proteins including G-actin
and myosin. The Rho/ROCK pathway is an important issue
for the regulation of cytoskeleton remodeling, and Rho,
ROCK, and MLCP are the key factors in this pathway [15].
There is evidence showing that Ang II is a regulator of
vascular permeability in inflammation [23,24], and the
Ang2e/e mice show a significantly attenuated response to
vascular permeability-inducing agents [25]. Moreover, the
in vitro experiment showed that Ang II is able to signifi-
cantly increase the NOX4 level and ROS production in lung
fibroblasts, which stimulates cell migration and collagen I
synthesis through the RhoA/Rock pathway [26]. Li et al [27]
also found that pinocembrin inhibited Ang II-induced vaso-
constriction in rat endothelium-denuded aortic rings, at
least in part, because of the blockade of the RhoA/ROCK
pathway. This indirectly suggests that Ang II may activate
the RhoA/ROCK pathway. Our results also showed the pro-
tein expressions of Rho, ROCK, and MLCKdthree key com-
ponents of the Rho/ROCK signaling pathwaydwhich
increased markedly in the lung after SAP, but reduced
dramatically in the presence of pretreatment with capto-
pril (an angiotensin-converting enzyme inhibitor). These
findings indicate that captopril pretreatment may reduce
Ang II and then inhibit the Rho/ROCK signaling pathway,
exerting protective effects on APALI. Of note, after SAP,
the expressions of both ROCK1 and ROCK2 increased
significantly. Following captopril pretreatment, only ROCK2
expression decreased dramatically, whereas ROCK1
expression decreased slightly. Thus, we speculate that the
inhibition of ROCK2 expression contributes more to the
protective effects of captopril pretreatment on APALI.
However, whether other pathways are also involved in theprotective effects of captopril pretreatment on APALI is
still unclear. In future studies, inhibitors targeting different
components of this pathway are required to confirm the
role of the Rho/ROCK signaling pathway in the pathogenesis
of APALI. Of note, there is evidence showing that captopril
is able to induce pancreatitis [28,29]. Whether this is
attributable to the individual sensitivity or the combined
therapy is still unclear. Thus, in the use of angiotensin-
converting enzyme inhibitors, clinicians should monitor
the patients closely, especially those with combined ther-
apy and/or pancreatic diseases.
Taken together, our study indicates that captopril pre-
treatment is able to protect the lung from SAP-induced lung
injury, which is, at least partially, ascribed to inhibition of
Ang II production and suppression of the Rho/ROCK
pathway. Thus, modalities targeting Ang II production may
become promising therapy for SAP/APALI. However, more
studies are required to confirm our findings prior to the
clinical application of this strategy.Acknowledgments
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